Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Syndrome of inappropriate antidiuresis (SIADH) is characterized by an imbalance of
antidiuretic vasopressin (AVP) secretion. The impaired AVP regulation leads to water
retention and secondary natriuresis and is a common cause for hyponatremia.
Especially chronic (>72h) SIADH is difficult to treat as standard therapeutic options (water
restriction, urea, salt tablets) often do not succeed in correction of hyponatremia, making
additional therapy necessary.
Empagliflozin is a sodium glucose co-transporter 2 (SGLT2)-inhibitor, which is a
well-tolerated treatment option for type 2 diabetes mellitus. The inhibition of SGLT2 in the
proximal tubule leads to renal excretion of glucose with subsequent osmotic diuresis. This
mechanism could result in a therapeutic effect in patients with chronic SIADH, as it
resembles the aquaretic effect of urea.
The aim of this study is to evaluate whether empagliflozin has an effect on the serum sodium
levels of patients with chronic SIADH.